...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Idea for Zenith
3
Jul 13, 2021 07:39PM
2
Jul 14, 2021 08:25AM
8
Jul 14, 2021 10:03AM
1
Jul 14, 2021 10:48AM
2
Jul 14, 2021 11:07AM
3
Jul 14, 2021 11:17AM
4
Jul 14, 2021 11:48AM
4
Jul 16, 2021 12:55PM
2
Jul 16, 2021 02:51PM
2
Jul 16, 2021 06:08PM

KOO - Zenith shareholders do not own Royalty Preferred Shares in RVX. Zenith Capital Corp. owns the RPS's and shareholders have value in them through their ZCC share ownership. That means that all shareholders own a proportionate share of the RPS value through their share price but do not own any portion of the actual shares.The RPS value raises the ZCC value which raises the ZCC share value. Below is from the 2013 NR about this.

"Pursuant to the Arrangement, Zenith was also issued royalty preferred shares in the capital of Resverlogix which will provide Zenith with a dividend equal to six to 12 percent of "Net Apo Revenue" as described in the Information Circular of Resverlogix dated April 29, 2013."

Share
New Message
Please login to post a reply